Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 12

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 12
---
 of at least $140,000 as part of the Loan from NewGenIvf, ASCA agreed to waive its termination rights and the right to receive any break-up fee due to Legacy NewGenIvf’s failure to deliver audited financial statements by no later than February 28, 2023. On December 6, 2023, the parties to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the “Second Amendment”) which amended and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf’s board of directors following the consummation of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf and three (3) of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii) provide for the conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary Shares in connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible assets immediately after the consummation of the Business Combination. On April 3, 2024, the Business Combination was consummated with the Company as the surviving entity. NewGenIvf’s Business With a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i) in vitro fertilization (“IVF”) treatment service, comprising traditional IVF and egg donation; and (ii) surrogacy and ancillary caring services. Currently, we have four clinics: two clinics in Thailand (one of which, whilst licensed, is yet to commence operations), one clinic in Cambodia, and one clinic in Kyrgyzstan.

<div align='center'>2</div>

For the years ended December 31,
2024 and 2023, NewGenIvf’s revenue was US$5,433,375 and US$5,136,153, and its net income/(loss) was US$(474,101) and US$108,418,
respectively.

Competitive Strengths

NewGenIvf believes that the
following competitive strengths have positioned it to meet growing opportunities in the fertility market across Asia-Pacific, and have
differentiated it from its competitors:

Broad-range Assisted Reproductive Service (“ARS”) Provider Offering